R&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014
Table 2
Where does the financing go?
Type of recipient
Amount received (US)
Percentage of total amount
Product Development Partnerships (PDPs)
425.171.917,91
49,20%
Academic and other research institutions
176.214.720,19
20,39%
Aggregate pharmaceutical and biotechnology companies
